Journal article

Association of Cerebrospinal Fluid Ferritin Level With Preclinical Cognitive Decline in APOE-epsilon 4 Carriers

Scott Ayton, Noel G Faux, Ashley I Bush

JAMA Neurology | AMER MEDICAL ASSOC | Published : 2017


Awarded by Alzheimer Disease Neuroimaging Initiative (ADNI) (National Institutes of Health)

Awarded by Department of Defense ADNI

Funding Acknowledgements

Data collection and sharing for this project were funded by the Alzheimer Disease Neuroimaging Initiative (ADNI) (National Institutes of Health grant U01 AG024904) and the Department of Defense ADNI (award No. W81XWH-12-2-0012). The ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer's Association; Alzheimer's Drug Discovery Foundation; BioClinica Inc; Biogen Idec Inc; BristolMyers Squibb Company; Eisai Inc; Elan Pharmaceuticals Inc; Eli Lilly and Company; F. Hoffmann-La Roche Ltd and its affiliated company Genentech Inc; GE Healthcare; Innogenetics, NV; IXICO Ltd; Janssen Alzheimer Immunotherapy Research & Development LLC; Johnson & Johnson Pharmaceutical Research & Development LLC; Medpace Inc; Merck & Co Inc; Meso Scale Diagnostics LLC; NeuroRx Research; Novartis Pharmaceuticals Corp; Pfizer Inc; Piramal Imaging; Servier; Synarc Inc; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health ( The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. Analysis was supported by funds from the Australian Research Council, the NHMRC, the Cooperative Research Centre for Mental Health (an Australian Government Initiative), Alzheimer's Australia, the Yulgilbar Foundation, and Perpetual-Salteri Foundation. The Florey Institute of Neuroscience and Mental Health acknowledges support from the Victorian government, in particular funding from the Operational Infrastructure Support grant.